Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Accumulated Expenses (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Accumulated Expenses for 3 consecutive years, with $11.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 43.04% to $11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.2 million through Dec 2025, up 43.04% year-over-year, with the annual reading at $11.2 million for FY2025, 43.04% up from the prior year.
  • Accumulated Expenses hit $11.2 million in Q4 2025 for Connect Biopharma Holdings, up from $8.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $11.2 million in Q4 2025 to a low of $7.2 million in Q1 2025.
  • Historically, Accumulated Expenses has averaged $8.8 million across 3 years, with a median of $8.4 million in 2025.
  • Biggest five-year swings in Accumulated Expenses: decreased 17.69% in 2024 and later skyrocketed 43.04% in 2025.
  • Year by year, Accumulated Expenses stood at $9.5 million in 2023, then dropped by 17.69% to $7.8 million in 2024, then surged by 43.04% to $11.2 million in 2025.
  • Business Quant data shows Accumulated Expenses for CNTB at $11.2 million in Q4 2025, $8.9 million in Q3 2025, and $7.9 million in Q2 2025.